vs
Avantor, Inc.（AVTR）与HARVARD BIOSCIENCE INC（HBIO）财务数据对比。点击上方公司名可切换其他公司
Avantor, Inc.的季度营收约是HARVARD BIOSCIENCE INC的70.1倍（$1.7B vs $23.7M）。Avantor, Inc.净利率更高（3.1% vs -12.0%，领先15.1%）。Avantor, Inc.同比增速更快（-1.4% vs -3.3%）。Avantor, Inc.自由现金流更多（$117.2M vs $-545.0K）。过去两年Avantor, Inc.的营收复合增速更高（-0.5% vs -1.6%）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
哈佛生物科学是一家全球生命科学设备开发商、制造商与销售商，其产品主要用于支撑科研开发与药物研发工作，目前该公司在纳斯达克上市，股票交易代码为HBIO。
AVTR vs HBIO — 直观对比
营收规模更大
AVTR
是对方的70.1倍
$23.7M
营收增速更快
AVTR
高出2.0%
-3.3%
净利率更高
AVTR
高出15.1%
-12.0%
自由现金流更多
AVTR
多$117.7M
$-545.0K
两年增速更快
AVTR
近两年复合增速
-1.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $23.7M |
| 净利润 | $52.4M | $-2.8M |
| 毛利率 | 31.5% | 59.7% |
| 营业利润率 | 7.6% | 7.2% |
| 净利率 | 3.1% | -12.0% |
| 营收同比 | -1.4% | -3.3% |
| 净利润同比 | -89.5% | -15916.7% |
| 每股收益（稀释后） | $0.08 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTRHBIO
| Q4 25 | $1.7B | $23.7M | ||
| Q3 25 | $1.6B | $20.6M | ||
| Q2 25 | $1.7B | $20.4M | ||
| Q1 25 | $1.6B | $21.8M | ||
| Q4 24 | $1.7B | $24.6M | ||
| Q3 24 | $1.7B | $22.0M | ||
| Q2 24 | $1.7B | $23.1M | ||
| Q1 24 | $1.7B | $24.5M |
净利润AVTRHBIO
| Q4 25 | $52.4M | $-2.8M | ||
| Q3 25 | $-711.8M | $-1.2M | ||
| Q2 25 | $64.7M | $-2.3M | ||
| Q1 25 | $64.5M | $-50.3M | ||
| Q4 24 | $500.4M | $18.0K | ||
| Q3 24 | $57.8M | $-4.8M | ||
| Q2 24 | $92.9M | $-2.9M | ||
| Q1 24 | $60.4M | $-4.7M |
毛利率AVTRHBIO
| Q4 25 | 31.5% | 59.7% | ||
| Q3 25 | 32.4% | 58.4% | ||
| Q2 25 | 32.9% | 56.4% | ||
| Q1 25 | 33.8% | 56.0% | ||
| Q4 24 | 33.4% | 57.1% | ||
| Q3 24 | 32.9% | 58.1% | ||
| Q2 24 | 34.1% | 57.2% | ||
| Q1 24 | 34.0% | 60.3% |
营业利润率AVTRHBIO
| Q4 25 | 7.6% | 7.2% | ||
| Q3 25 | -40.0% | 1.0% | ||
| Q2 25 | 7.7% | -4.0% | ||
| Q1 25 | 9.3% | -228.1% | ||
| Q4 24 | 37.8% | 0.0% | ||
| Q3 24 | 7.3% | -8.5% | ||
| Q2 24 | 10.3% | -9.0% | ||
| Q1 24 | 8.7% | -9.3% |
净利率AVTRHBIO
| Q4 25 | 3.1% | -12.0% | ||
| Q3 25 | -43.8% | -6.0% | ||
| Q2 25 | 3.8% | -11.2% | ||
| Q1 25 | 4.1% | -231.2% | ||
| Q4 24 | 29.7% | 0.1% | ||
| Q3 24 | 3.4% | -21.9% | ||
| Q2 24 | 5.5% | -12.7% | ||
| Q1 24 | 3.6% | -19.1% |
每股收益（稀释后）AVTRHBIO
| Q4 25 | $0.08 | $-0.06 | ||
| Q3 25 | $-1.04 | $-0.03 | ||
| Q2 25 | $0.09 | $-0.05 | ||
| Q1 25 | $0.09 | $-1.14 | ||
| Q4 24 | $0.73 | $0.01 | ||
| Q3 24 | $0.08 | $-0.11 | ||
| Q2 24 | $0.14 | $-0.07 | ||
| Q1 24 | $0.09 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | $8.6M |
| 总债务越低越好 | $3.9B | $35.9M |
| 股东权益账面价值 | $5.6B | $13.7M |
| 总资产 | $11.8B | $80.1M |
| 负债/权益比越低杠杆越低 | 0.71× | 2.61× |
8季度趋势，按日历期对齐
现金及短期投资AVTRHBIO
| Q4 25 | $365.4M | $8.6M | ||
| Q3 25 | $251.9M | $6.8M | ||
| Q2 25 | $449.4M | $7.4M | ||
| Q1 25 | $315.7M | $5.5M | ||
| Q4 24 | $261.9M | $4.1M | ||
| Q3 24 | $285.3M | $4.6M | ||
| Q2 24 | $272.6M | $4.0M | ||
| Q1 24 | $234.9M | $4.3M |
总债务AVTRHBIO
| Q4 25 | $3.9B | $35.9M | ||
| Q3 25 | $3.9B | $34.0M | ||
| Q2 25 | $4.2B | $34.9M | ||
| Q1 25 | $4.1B | $36.4M | ||
| Q4 24 | $4.1B | $37.0M | ||
| Q3 24 | $4.9B | $34.9M | ||
| Q2 24 | $5.1B | $35.7M | ||
| Q1 24 | $5.3B | $35.6M |
股东权益AVTRHBIO
| Q4 25 | $5.6B | $13.7M | ||
| Q3 25 | $5.6B | $14.1M | ||
| Q2 25 | $6.3B | $15.7M | ||
| Q1 25 | $6.1B | $14.8M | ||
| Q4 24 | $6.0B | $63.3M | ||
| Q3 24 | $5.6B | $65.3M | ||
| Q2 24 | $5.4B | $67.2M | ||
| Q1 24 | $5.3B | $68.8M |
总资产AVTRHBIO
| Q4 25 | $11.8B | $80.1M | ||
| Q3 25 | $11.7B | $78.0M | ||
| Q2 25 | $12.8B | $80.1M | ||
| Q1 25 | $12.3B | $79.8M | ||
| Q4 24 | $12.1B | $126.6M | ||
| Q3 24 | $12.8B | $131.2M | ||
| Q2 24 | $12.7B | $128.9M | ||
| Q1 24 | $12.8B | $133.2M |
负债/权益比AVTRHBIO
| Q4 25 | 0.71× | 2.61× | ||
| Q3 25 | 0.69× | 2.41× | ||
| Q2 25 | 0.67× | 2.22× | ||
| Q1 25 | 0.67× | 2.45× | ||
| Q4 24 | 0.68× | 0.58× | ||
| Q3 24 | 0.89× | 0.53× | ||
| Q2 24 | 0.94× | 0.53× | ||
| Q1 24 | 1.00× | 0.52× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | $-96.0K |
| 自由现金流经营现金流 - 资本支出 | $117.2M | $-545.0K |
| 自由现金流率自由现金流/营收 | 7.0% | -2.3% |
| 资本支出强度资本支出/营收 | 2.1% | 1.9% |
| 现金转化率经营现金流/净利润 | 2.91× | — |
| 过去12个月自由现金流最近4个季度 | $495.0M | $5.5M |
8季度趋势，按日历期对齐
经营现金流AVTRHBIO
| Q4 25 | $152.7M | $-96.0K | ||
| Q3 25 | $207.4M | $1.1M | ||
| Q2 25 | $154.4M | $2.8M | ||
| Q1 25 | $109.3M | $3.0M | ||
| Q4 24 | $173.3M | $1.7M | ||
| Q3 24 | $244.8M | $-842.0K | ||
| Q2 24 | $281.1M | $-846.0K | ||
| Q1 24 | $141.6M | $1.4M |
自由现金流AVTRHBIO
| Q4 25 | $117.2M | $-545.0K | ||
| Q3 25 | $171.7M | $877.0K | ||
| Q2 25 | $124.8M | $2.7M | ||
| Q1 25 | $81.3M | $2.5M | ||
| Q4 24 | $145.8M | $1.4M | ||
| Q3 24 | $204.0M | $-1.7M | ||
| Q2 24 | $235.3M | $-1.7M | ||
| Q1 24 | $106.9M | $758.0K |
自由现金流率AVTRHBIO
| Q4 25 | 7.0% | -2.3% | ||
| Q3 25 | 10.6% | 4.3% | ||
| Q2 25 | 7.4% | 13.0% | ||
| Q1 25 | 5.1% | 11.4% | ||
| Q4 24 | 8.6% | 5.8% | ||
| Q3 24 | 11.9% | -7.8% | ||
| Q2 24 | 13.8% | -7.2% | ||
| Q1 24 | 6.4% | 3.1% |
资本支出强度AVTRHBIO
| Q4 25 | 2.1% | 1.9% | ||
| Q3 25 | 2.2% | 1.0% | ||
| Q2 25 | 1.8% | 0.4% | ||
| Q1 25 | 1.8% | 2.4% | ||
| Q4 24 | 1.6% | 1.2% | ||
| Q3 24 | 2.4% | 4.0% | ||
| Q2 24 | 2.7% | 3.5% | ||
| Q1 24 | 2.1% | 2.6% |
现金转化率AVTRHBIO
| Q4 25 | 2.91× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 0.35× | 95.83× | ||
| Q3 24 | 4.24× | — | ||
| Q2 24 | 3.03× | — | ||
| Q1 24 | 2.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
HBIO
| Instruments Equipment Software And Accessories | $21.6M | 91% |
| Service Maintenance And Warranty Contracts | $2.1M | 9% |
